

Edgar Filing: LA JOLLA PHARMACEUTICAL CO - Form SC 13G

LA JOLLA PHARMACEUTICAL CO
Form SC 13G
February 14, 2006

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G

Under the Securities Exchange Act of 1934
(Amendment No. 1)

La Jolla Pharmaceutical Company

(Name of Issuer)

Common Stock

(Title of Class of Securities)

503459307

(CUSIP Number)

December 31, 2005

(Date of Event which Required Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)
 Rule 13d-1(c)
 Rule 13d-1(d)

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13G

- 1 NAME OF REPORTING PERSON
SS. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Columbia Wanger Asset Management, L.P. 04-3519872
- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)
(b)
Not Applicable
- 3 SEC USE ONLY
- 4 CITIZENSHIP OR PLACE OF ORGANIZATION

Edgar Filing: LA JOLLA PHARMACEUTICAL CO - Form SC 13G

Delaware

	5	SOLE VOTING POWER 1,125,000	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	6	SHARED VOTING POWER 0	
	7	SOLE DISPOSITIVE POWER 1,125,000	
	8	SHARED DISPOSITIVE POWER 0	
9		AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,125,000	
10		CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES <input type="checkbox"/>	
		Not Applicable	
11		PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 7.6%	
12		TYPE OF REPORTING PERSON IA	

1 NAME OF REPORTING PERSON
SS. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
WAM Acquisition GP, Inc.

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a)
(b)
Not Applicable

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware

	5	SOLE VOTING POWER 0	
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	6	SHARED VOTING POWER 1,125,000	
	7	SOLE DISPOSITIVE POWER 0	
	8	SHARED DISPOSITIVE POWER	

Edgar Filing: LA JOLLA PHARMACEUTICAL CO - Form SC 13G

1,125,000

- 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,125,000
- 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
- Not Applicable
- 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
7.6%
- 12 TYPE OF REPORTING PERSON
CO

- Item 1. (a). Name of Issuer: La Jolla Pharmaceutical Company
- (b). Address of Issuer's Principal Executive Offices:

6455 Nancy Ridge Drive
San Diego, CA 92121
- Item 2. (a). Name of Person Filing:

Columbia Wanger Asset Management L.P. ("WAM")
WAM Acquisition GP, Inc., the general partner of WAM
("WAM GP")
- (b). Address of Principal Business Office or, if none, Residence:

WAM and WAM GP are both located at:

227 West Monroe Street, Suite 3000
Chicago, Illinois 60606
- (c). Citizenship or Place of Organization:

WAM is a Delaware limited partnership, WAM GP is a Delaware corporation.
- (d). Title of Class of Securities:

Common Stock
- (e). CUSIP Number:

503459307
- Item 3. If this statement is filed pursuant to sections 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
- (a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
- (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
- (c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c.);
- (d) Investment company registered under section 8 of the

Edgar Filing: LA JOLLA PHARMACEUTICAL CO - Form SC 13G

- (e) Investment Company Act of 1940 (15 U.S.C. 80a-8);
An investment adviser in accordance with section 240.13d-1(b)(1)(ii)(E) (WAM is an Investment Adviser registered under section 203 of the Investment Advisers Act of 1940; WAM GP is the General Partner of the Investment Adviser.);
- (f) An employee benefit plan or endowment fund in accordance with section 240.13d-1(b)(1)(ii)(F);
- (g) A parent holding company or control person in accordance with section 240.13d-1(b)(1)(ii)(G);
- (h) A savings associations as defined in section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j) Group, in accordance with section 240.13d-1(b)(1)(ii)(J).

If this statement is filed pursuant to Rule 13d-1(c), check this box.

Item 4. Ownership (at December 31, 2005).

(a). Amount beneficially owned within the meaning of rule 13d-3::

- (i) WAM: 1,125,000
- (ii) WAM GP: 1,125,000

(b). Percent of class:

- (i) WAM: 7.6%
- (ii) WAM GP: 7.6%

(c). Number of shares as to which the person has:

(1) Sole power to vote or to direct the vote:

- (i) WAM: 1,125,000
- (ii) WAM GP: 0

(2) Shared power to vote or to direct the vote:

- (i) WAM: 0
- (ii) WAM GP: 1,125,000

(3) Sole power to dispose or to direct the disposition of:

- (i) WAM: 2,102,000
- (ii) WAM GP: 0

(4) Shared power to dispose or to direct the disposition of:

- (i) WAM: 0
- (ii) WAM GP: 1,125,000

Item 5. Ownership of Five Percent or Less of a Class:

Not Applicable

Item 6. Ownership of More Than Five Percent on Behalf of Another

Edgar Filing: LA JOLLA PHARMACEUTICAL CO - Form SC 13G

Person:

The shares reported herein include the shares held by Columbia Acorn Trust (CAT), a Massachusetts business trust that is advised by WAM, a Delaware limited partnership. CAT holds 7.4% shares of the Issuer's shares.

Item 7. Identification and Classification of Subsidiaries which Acquired the Security Being Reported on by the Parent Holding Company:

Not Applicable

Item 8. Identification and Classification of Members of the Group:

Not Applicable

Item 9. Notice of Dissolution of Group:

Not Applicable

Item 10. Certification:

(a) The following certification shall be included if the statement is filed pursuant to 240.13d-1(b):

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Disclaimer

In accordance with Rule 13d-4 of the Securities Exchange Act of 1934, each of the persons filing this statement expressly disclaim the beneficial ownership of the securities covered by this statement and the filing of this report shall not be construed as an admission by such persons that they are the beneficial owners of such securities.

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 14, 2006

The undersigned corporation, on the date above written, agrees and consents to the joint filing on its behalf of this Schedule 13G in connection with its beneficial ownership of the security reported herein.

WAM Acquisition GP, Inc.
for itself and as general partner of
COLUMBIA WANGER ASSET

Edgar Filing: LA JOLLA PHARMACEUTICAL CO - Form SC 13G

MANAGEMENT, L.P.

By: /s/ Bruce H. Lauer

Bruce H. Lauer
Senior Vice President and Secretary

Exhibit Index

Exhibit 1 Joint Filing Agreement dated as of February 14, 2006 by and among
Columbia Wanger Asset Management, L.P.; WAM Acquisition GP, Inc.;
and Columbia Acorn Trust.

EXHIBIT 1

JOINT FILING AGREEMENT

The undersigned hereby agree to the joint filing of the Schedule 13G to
which this Agreement is attached.

Dated: February 14, 2006

WAM Acquisition GP, Inc.
for itself and as general partner of
COLUMBIA WANGER ASSET
MANAGEMENT, L.P.

By: /s/ Bruce H. Lauer

Senior Vice President and Secretary

COLUMBIA ACORN TRUST

By: /s/ Bruce H. Lauer

Senior Vice President and Secretary